The only significant variable associated with higher OS was initial attainment of CR/CRi after induction therapy (65.2% vs. 20% at 1-year; P = 0.005) (Fig. 2), stressing the impact of optimizing upfront CML-MBP therapy. This evidence concerns the gene MBP and chronic myelogenous leukemia, BCR-ABL1 positive.